Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l.—making Covis a wholly-owned subsidiary of Azurity.

This acquisition reinforces Azurity’s leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale.

Azurity’s acquisition of Covis expands its therapeutic portfolio, global footprint, and positions it as a key biopharma partner. The integration also accelerates innovation and enhances Azurity’s commercial model, benefiting patients worldwide.

“We are excited to welcome Covis Pharma to Azurity,” said Ronald Scarboro, CEO of Azurity. “The efforts of colleagues at both companies, their devotion to overlooked patients, and our culture of execution have brought us together to build this unique, highly differentiated pharmaceutical company. I look forward to all that we will accomplish as we grow globally and embrace new opportunities, driven by our purpose.”

“I am delighted that Azurity recognized the accomplishments and potential of Covis, and am thankful for the tireless efforts of Covis colleagues in support of patients that benefit from the company’s products,” said Rajiv De Silva, Chairman of the Board of Covis. “I am confident that the two companies will be able to untap each other’s highly complementary capabilities to accelerate development and commercialization of necessary medicines to underserved patients.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.